ArticleGenes2026

AKT Inhibitor Capivasertib as a Target for Osimertinib Combination Therapy in Lung Adenocarcinoma with

Takuya Tokunaga et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.